Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 70.17 Million EUR | -6.77% |
| 2022 | 75.27 Million EUR | 1.4% |
| 2021 | 74.23 Million EUR | -60.02% |
| 2020 | 185.69 Million EUR | 1.13% |
| 2019 | 183.61 Million EUR | 8.28% |
| 2018 | 169.58 Million EUR | 3.56% |
| 2017 | 163.75 Million EUR | 2519.18% |
| 2016 | 6.25 Million EUR | 9.59% |
| 2015 | 5.7 Million EUR | -13.51% |
| 2014 | 6.59 Million EUR | -10.24% |
| 2013 | 7.34 Million EUR | -31.33% |
| 2012 | 10.7 Million EUR | -24.08% |
| 2011 | 14.09 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 9.76 Million EUR | -3.76% |
| 2008 | 10.15 Million EUR | 174.49% |
| 2007 | 3.69 Million EUR | -16.25% |
| 2006 | 4.41 Million EUR | -21.62% |
| 2005 | 5.63 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 62.18 Million EUR | 0.0% |
| 2023 FY | 70.17 Million EUR | -6.77% |
| 2023 Q2 | 75.42 Million EUR | 0.0% |
| 2023 Q4 | 70.17 Million EUR | 0.0% |
| 2022 Q2 | 74.74 Million EUR | 0.0% |
| 2022 FY | 75.27 Million EUR | 1.4% |
| 2022 Q4 | 75.27 Million EUR | 0.0% |
| 2021 Q4 | 74.23 Million EUR | 0.0% |
| 2021 FY | 74.23 Million EUR | -60.02% |
| 2021 Q2 | 70.93 Million EUR | 0.0% |
| 2020 Q4 | 185.69 Million EUR | 0.0% |
| 2020 Q2 | 184.63 Million EUR | 0.0% |
| 2020 FY | 185.69 Million EUR | 1.13% |
| 2019 Q4 | 183.61 Million EUR | 0.0% |
| 2019 Q2 | 182.03 Million EUR | 0.0% |
| 2019 FY | 183.61 Million EUR | 8.28% |
| 2018 Q4 | 169.58 Million EUR | 0.0% |
| 2018 Q2 | 163.95 Million EUR | 0.0% |
| 2018 FY | 169.58 Million EUR | 3.56% |
| 2017 Q4 | 163.75 Million EUR | 0.0% |
| 2017 FY | 163.75 Million EUR | 2519.18% |
| 2017 Q2 | 8.5 Million EUR | 0.0% |
| 2016 Q4 | 6.25 Million EUR | 0.0% |
| 2016 FY | 6.25 Million EUR | 9.59% |
| 2016 Q2 | 5.98 Million EUR | 0.0% |
| 2015 Q4 | 5.7 Million EUR | 0.0% |
| 2015 FY | 5.7 Million EUR | -13.51% |
| 2015 Q2 | 6.24 Million EUR | 0.0% |
| 2014 Q4 | 6.59 Million EUR | 0.0% |
| 2014 Q2 | 7.03 Million EUR | 0.0% |
| 2014 FY | 6.59 Million EUR | -10.24% |
| 2013 Q4 | 7.34 Million EUR | 0.0% |
| 2013 Q2 | 8.8 Million EUR | 0.0% |
| 2013 FY | 7.34 Million EUR | -31.33% |
| 2012 Q4 | 10.7 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 10.7 Million EUR | -24.08% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | 14.09 Million EUR | 0.0% |
| 2011 FY | 14.09 Million EUR | 0.0% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 FY | 9.76 Million EUR | -3.76% |
| 2009 Q4 | 9.76 Million EUR | 0.0% |
| 2009 Q2 | 1.89 Million EUR | 0.0% |
| 2008 FY | 10.15 Million EUR | 174.49% |
| 2007 FY | 3.69 Million EUR | -16.25% |
| 2006 FY | 4.41 Million EUR | -21.62% |
| 2005 FY | 5.63 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1970.147% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -26.529% |
| Adocia SA | 13.08 Million EUR | -436.201% |
| Aelis Farma SA | 4.03 Million EUR | -1637.94% |
| Biophytis S.A. | 8.27 Million EUR | -748.585% |
| Advicenne S.A. | 17.42 Million EUR | -302.743% |
| genOway Société anonyme | 7.23 Million EUR | -870.193% |
| IntegraGen SA | 1.12 Million EUR | -6139.514% |
| Medesis Pharma S.A. | 1.2 Million EUR | -5748.167% |
| Neovacs S.A. | 650 Thousand EUR | -10696.615% |
| NFL Biosciences SA | 62.17 Thousand EUR | -112773.548% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1510.877% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -2483.075% |
| Sensorion SA | 2.86 Million EUR | -2346.26% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1826.368% |
| TME Pharma N.V. | 1.16 Million EUR | -5918.696% |
| Valbiotis SA | 6.87 Million EUR | -920.326% |
| TheraVet SA | 1.15 Million EUR | -5950.521% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -679.929% |
| argenx SE | 18.1 Million EUR | -287.611% |
| BioSenic S.A. | 28.16 Million EUR | -149.203% |
| Celyad Oncology SA | 902 Thousand EUR | -7680.266% |
| DBV Technologies S.A. | 13.01 Million USD | -439.059% |
| Galapagos NV | 9.59 Million EUR | -631.326% |
| GeNeuro SA | 7.73 Million EUR | -806.95% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -1225.614% |
| Innate Pharma S.A. | 39.89 Million EUR | -75.916% |
| Inventiva S.A. | 37.4 Million EUR | -87.607% |
| MaaT Pharma SA | 14.07 Million EUR | -398.6% |
| MedinCell S.A. | 58.96 Million EUR | -19.024% |
| Nanobiotix S.A. | 50.56 Million EUR | -38.788% |
| Onward Medical N.V. | 16.87 Million EUR | -315.894% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -412.725% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -53.224% |
| Oxurion NV | 12.33 Million EUR | -468.98% |
| Pharming Group N.V. | 155.29 Million EUR | 54.809% |
| Poxel S.A. | 46.9 Million EUR | -49.633% |
| GenSight Biologics S.A. | 18.42 Million EUR | -280.823% |
| Transgene SA | 1.25 Million EUR | -5482.975% |
| Financière de Tubize SA | 79.2 Million EUR | 11.391% |
| UCB SA | 3.03 Billion EUR | 97.69% |
| Valneva SE | 208.81 Million EUR | 66.392% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -184578.947% |